Risk stratification after ST-segment elevation myocardial infarction

ABSTRACT Introduction: Risk stratification according to the timing of assessment, treatment modality and outcome of interest is highly advisable in patients with ST-elevation myocardial infarction (STEMI) to identify optimal treatment strategies, proper length of hospital stay and correct timing of follow-up. Areas covered: This review is an overview summarizing the characteristics and performance of available risk-scoring systems for STEMI. In particular, we sought to highlight the characteristics of STEMI cohorts used for derivation and validation of the available algorithms and appraise their discrimination ability, calibration and global accuracy. Expert commentary: Applying the appropriate score, customized on patients’ profile and clinical characteristics at presentation or during the hospitalization, might prove useful to improve the overall quality of care provided to STEMI patients.

[1]  G. Stone,et al.  Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials , 2016, European heart journal. Acute cardiovascular care.

[2]  A. Mebazaa,et al.  Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients - Multiple biomarkers prospective cohort study. , 2016, International journal of cardiology.

[3]  M. Sabatine,et al.  Multimarker Risk Stratification in Patients With Acute Myocardial Infarction , 2016, Journal of the American Heart Association.

[4]  H. Kisacik,et al.  Platelet to Lymphocyte Ratio as a Prognostic Marker of In-Hospital and Long-Term Major Adverse Cardiovascular Events in ST-Segment Elevation Myocardial Infarction , 2016, Angiology.

[5]  S. Doğan,et al.  The value of the Clinical SYNTAX Score in predicting long-term prognosis in patients with ST-segment elevation myocardial infarction who have undergone primary percutaneous coronary intervention , 2016, Coronary artery disease.

[6]  M. Loutfi,et al.  Impact of the Residual SYNTAX Score on Outcomes of Revascularization in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease , 2016, Clinical Medicine Insights. Cardiology.

[7]  A. Elguindy,et al.  Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI , 2015, Global cardiology science & practice.

[8]  C. Hamm,et al.  Reference Values and Release Kinetics of B-Type Natriuretic Peptide Signal Peptide in Patients with Acute Myocardial Infarction. , 2015, Clinical chemistry.

[9]  K. Dickstein,et al.  Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial , 2015, European journal of preventive cardiology.

[10]  L. Dušek,et al.  GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction , 2015, PloS one.

[11]  Harlan M Krumholz,et al.  Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study , 2015, The Lancet.

[12]  L. Azzalini,et al.  Feasibility and Safety of an Early Discharge Strategy after Low-Risk Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: The EDAMI Pilot Trial , 2015, Cardiology.

[13]  P. Serruys,et al.  Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction , 2014, Heart.

[14]  M. Nakano,et al.  Diagnostic accuracy of Global Registry of Acute Coronary Events (GRACE) risk score in ST-elevation myocardial infarction for in-hospital and 360-day mortality in Japanese patients. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[15]  H. Suryapranata,et al.  Early Discharge After Primary Percutaneous Coronary Intervention: The Added Value of N‐Terminal Pro–Brain Natriuretic Peptide to the Zwolle Risk Score , 2014, Journal of the American Heart Association.

[16]  P. Serruys,et al.  The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: a substudy of the COMFORTABLE AMI trial. , 2014, International journal of cardiology.

[17]  Yan Zhang,et al.  Stent for Life Initiative: leading example in building STEMI systems of care in emerging countries. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  L. Correia,et al.  Prognostic Value of TIMI Score versus GRACE Score in ST-segment Elevation Myocardial Infarction , 2014, Arquivos brasileiros de cardiologia.

[19]  D. De Bacquer,et al.  Gender, TIMI risk score and in-hospital mortality in STEMI patients undergoing primary PCI: results from the Belgian STEMI registry. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[20]  J. P. Lopes,et al.  Is it possible to simplify risk stratification scores for patients with ST-segment elevation myocardial infarction undergoing primary angioplasty? , 2013, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[21]  E. Scruth,et al.  Risk score comparison of outcomes in patients presenting with ST-elevation myocardial infarction treated with percutaneous coronary intervention , 2013, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[22]  D. Capodanno.  Beyond the SYNTAX score--advantages and limitations of other risk assessment systems in left main percutaneous coronary intervention. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[23]  Antonio Colombo,et al.  Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II , 2013, The Lancet.

[24]  P. Damman,et al.  Short- and long-term prognostic value of the TIMI risk score after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. , 2013, Journal of interventional cardiology.

[25]  E. Antman,et al.  Dynamic TIMI Risk Score for STEMI , 2013, Journal of the American Heart Association.

[26]  D. Atar,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. , 2012, European heart journal.

[27]  Alan Yean Yip Fong,et al.  An Asian Validation of the TIMI Risk Score for ST-Segment Elevation Myocardial Infarction , 2012, PloS one.

[28]  Giuseppe Biondi-Zoccai,et al.  TIMI, GRACE and alternative risk scores in Acute Coronary Syndromes: a meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. , 2012, Contemporary clinical trials.

[29]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[30]  J. Messenger,et al.  Trends and predictors of length of stay after primary percutaneous coronary intervention: a report from the CathPCI registry. , 2011, American Heart Journal.

[31]  Anna Kozieradzka,et al.  GRACE, TIMI, Zwolle and CADILLAC risk scores--do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? , 2011, International journal of cardiology.

[32]  E. Braunwald,et al.  The evolving epidemiology of acute coronary syndromes , 2011, Nature Reviews Cardiology.

[33]  D. Capodanno,et al.  Global risk classification and clinical SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) score in patients undergoing percutaneous or surgical left main revascularization. , 2011, JACC. Cardiovascular interventions.

[34]  F. Van de Werf,et al.  Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.

[35]  P. Armstrong,et al.  A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Results From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial , 2010, Circulation. Cardiovascular interventions.

[36]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[37]  K. Eagle,et al.  Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores , 2009, PloS one.

[38]  E. Antman,et al.  Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. , 2009, American heart journal.

[39]  G. Licciardello,et al.  Early discharge in acute myocardial infarction after clinical and angiographic risk assessment , 2008, Journal of cardiovascular medicine.

[40]  R. Kornowski,et al.  Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. , 2008, The American journal of cardiology.

[41]  K. Eagle,et al.  Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. , 2008, European heart journal.

[42]  K. Kamiński,et al.  Original article TIMI Risk Score accurately predicts risk of death in 30-day and one-year follow-up in STEMI patients treated with primary percutaneous coronary interventions , 2007 .

[43]  Sohail Q Khan,et al.  N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction , 2007, Heart.

[44]  M. Grabowski,et al.  Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. , 2007, International journal of cardiology.

[45]  G. Filippatos,et al.  The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. , 2006, European heart journal.

[46]  K. Weinfurt,et al.  Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. , 2005, American heart journal.

[47]  B. Gersh,et al.  Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. , 2005, Journal of the American College of Cardiology.

[48]  E. Antman,et al.  Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. , 2004, Journal of the American College of Cardiology.

[49]  E. Antman,et al.  B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. , 2004, Journal of the American College of Cardiology.

[50]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. , 2004, Journal of the American Medical Association (JAMA).

[51]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .

[52]  Felix Zijlstra,et al.  Prognostic Assessment of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty: Implications for Early Discharge , 2004, Circulation.

[53]  G. Stone,et al.  Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). , 2004, The American journal of cardiology.

[54]  C. Gross,et al.  Validity of a Simple ST-Elevation Acute Myocardial Infarction Risk Index: Are Randomized Trial Prognostic Estimates Generalizable to Elderly Patients? , 2003, Circulation.

[55]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[56]  David A Morrow,et al.  A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy , 2001, The Lancet.

[57]  E. Antman,et al.  Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. , 2001, JAMA.

[58]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[59]  G. Stone,et al.  Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. , 2000, The New England journal of medicine.

[60]  K. Lee,et al.  Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. , 2000, Circulation.

[61]  Bruce R. Brodie,et al.  Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction , 1999 .

[62]  M. Funk,et al.  Predicting hospital mortality in patients with acute myocardial infarction. , 1994, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[63]  C. Gottschall,et al.  Accuracy of dedicated risk scores in patients undergoing primary percutaneous coronary intervention in daily clinical practice. , 2014, The Canadian journal of cardiology.

[64]  P. Serruys,et al.  Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted Fro , 2014, JACC. Cardiovascular interventions.

[65]  P. Damman,et al.  MULTIPLE BIOMARKERS AT ADMISSION SIGNIFICANTLY IMPROVE THE PREDICTION OF MORTALITY IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION , 2013 .

[66]  H. González-Pacheco,et al.  The TIMI risk score for STEMI predicts in-hospital mortality and adverse events in patients without cardiogenic shock undergoing primary angioplasty. , 2012, Archivos de cardiologia de Mexico.

[67]  P. Kranke,et al.  Quantifying prognosis with risk predictions. , 2012, European journal of anaesthesiology.

[68]  K. Mahaffey,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .

[69]  D. McManus,et al.  Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. , 2011, The American journal of medicine.

[70]  P. Serruys,et al.  Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Me , 2011, JACC. Cardiovascular interventions.

[71]  B. Gersh,et al.  Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction , 2011 .

[72]  Rizwan Afzal,et al.  Safety and feasibility of early hospital discharge in ST-segment elevation myocardial infarction--a prospective and randomized trial in low-risk primary percutaneous coronary intervention patients (the Safe-Depart Trial). , 2010, American heart journal.

[73]  K. Kamiński,et al.  TIMI Risk Score accurately predicts risk of death in 30-day and one-year follow-up in STEMI patients treated with primary percutaneous coronary interventions. , 2007, Kardiologia polska.

[74]  J. Tu,et al.  Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. , 2007, The Canadian journal of cardiology.

[75]  A. Jeremias,et al.  Vascular Health and Risk Management Dovepress the Utility of Troponin Measurement to Detect Myocardial Infarction: Review of the Current Findings , 2022 .